Skip to main content

and
Your search also matched 4 preview-only Content is preview-only when you or your institution have not yet subscribed to it.

By making our abstracts and previews universally accessible we help you purchase only the content that is relevant to you.
results, e.g.

Tolvaptan slows disease progression in late-stage ADPKD

Include preview-only content
  1. Article

    Chronic kidney disease and the global public health agenda: an international consensus

    Early detection is a key strategy to prevent kidney disease, its progression and related complications, but numerous studies show that awareness of kidney disease at the population level is low. Therefore, inc...

    Anna Francis, Meera N. Harhay, Albert C. M. Ong in Nature Reviews Nephrology (2024)

  2. Article

    Open Access

    HYDROchlorothiazide versus placebo to PROTECT polycystic kidney disease patients and improve their quality of life: study protocol and rationale for the HYDRO-PROTECT randomized controlled trial

    Autosomal dominant polycystic kidney disease (ADPKD) leads to progressive renal cyst formation and loss of kidney function in most patients. Vasopressin 2 receptor antagonists (V2RA) like tolvaptan are current...

    Thomas Bais, Esther Meijer, Bart J. Kramers, Priya Vart, Marc Vervloet in Trials (2024)

  3. Article

    Open Access

    Barriers and facilitators to the implementation of guidelines in rare diseases: a systematic review

    Rare diseases present a challenge to guideline implementation due to a low prevalence in the general population and the unfamiliarity of healthcare professionals. Existing literature in more common diseases re...

    Matthew Gittus, Jiehan Chong, Anthea Sutton in Orphanet Journal of Rare Diseases (2023)

  4. Article

    Open Access

    A rapid high-performance semi-automated tool to measure total kidney volume from MRI in autosomal dominant polycystic kidney disease

    To develop a high-performance, rapid semi-automated method (Sheffield TKV Tool) for measuring total kidney volume (TKV) from magnetic resonance images (MRI) in patients with autosomal dominant polycystic kidne...

    Roslyn J. Simms, Trushali Doshi, Peter Metherall, Desmond Ryan in European Radiology (2019)

  5. Article

    Open Access

    A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model

    Autosomal dominant polycystic kidney disease (ADPKD) is the leading inheritable cause of end-stage renal disease (ESRD); however, the natural course of disease progression is heterogeneous between patients. Th...

    Phil McEwan, Hayley Bennett Wilton, Albert C. M. Ong, Bjarne Ørskov in BMC Nephrology (2018)

  6. Article

    Open Access

    Standardised Outcomes in Nephrology—Polycystic Kidney Disease (SONG-PKD): study protocol for establishing a core outcome set in polycystic kidney disease

    Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening inherited kidney disease and is responsible for 5–10% of cases of end-stage kidney disease (ESKD). Cystic ki...

    Yeoungjee Cho, Benedicte Sautenet, Gopala Rangan, Jonathan C. Craig in Trials (2017)